RNA-Based Therapeutics And Vaccines Market: By Product, By Indication, By Type and Region Forecast 2019-2030

RNA-Based Therapeutics And Vaccines Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (RNA-based Therapeutics, RNA-based Vaccines), By Indication (Oncology, Ophthalmic Disorders, Immunology, Cardiovascular Disorders, Infectious Diseases, Genetic Disorders, CNS Disorders, Others), By Type (siRNA, ASO, mRNA, saRNA, miRNA, tRNA, Aptamers, Others) and Region Forecast 2019-2030

RNA-Based Therapeutics and Vaccines Market size was valued at US$ 61,296.3 million in 2023 and is poised to grow at a CAGR of 3.8% from 2024-2030. The market is likely to experience a steep rise in its growth during the forecast period due to the rise in the prevalence of chronic diseases such as diabetes, tuberculosis, cancer, and certain other cardiovascular conditions. RNA therapeutics and vaccines hold the distinction of providing better stability as compared to their counterparts. Though the majority of them are under trials (as mentioned above), they are increasingly preferred when it comes to treating obstinate disorders. Rapid advancement in technologies particularly in the healthcare sector has significantly lifted the demand for RNA-based therapeutics and vaccines. 

The healthcare sector has been bringing their minds together to bring stability to the RNA molecules in the body with limited bioavailability. It is the RNA therapeutics that when combined with protein/ lipid nanoparticles provide better stability. Despite being in a clinical research phase the RNA therapeutics has been extensively explored with a primary aim to treat difficult diseases. One of the major factors that is driving the market is the rise of promising technologies such as antisense technology, smart technology, and RNAi interference technology. The market primarily finds cures for cancer and infectious diseases and since the pool of patients is large, the demand for the market subsequently is also high. This creates a huge opportunity globally for market. The lack of alternative treatment options for rare diseases further boosted the growth of RNA-based therapeutics and vaccines during the forecast period. Aiding the growth of this market, the increasing focus of legislative bodies on developing reimbursement policies has fueled the development process of RNA molecules.

Key Developments

  • In Jan 2022, Novartis and Alnylam have agreed to collaborate on the discovery and development of siRNA-based targeted therapy to restore functional liver cells in patients with end-stage liver disease. The agreement will bring Alnylam proprietary siRNA technology to bear on liver target identified by Novartis researchers.
  • In April 2020, Blackstone and Alnylam Entered Into $2 Billion Strategic Financing Collaboration to Accelerate the Advancement of RNAi Therapeutics

Rna Based Therapeutics And Vaccines Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

3.8%

Largest Market

North America

Fastest Growing Market

North America

RNA based Therapeutics and Vaccines Market Dynamics

Gene silencing potential of RNA based therapeutics is the primary driver for the growth of this market. The other drivers include target specificity and selectivity of RNA therapeutics, more intense product focus versus platform technologies and virtual drug development models that enable companies to reduce the research cost. Factors such as expensive research, high failure rated accompanied with problems faced in drug delivery are anticipated to bring down the RNA based therapeutics and vaccines market.

Rna Based Therapeutics And Vaccines Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 61,296.3 million

Market CAGR

3.8%

By Product Type

  • RNA-based Therapeutics,
  • RNA-based Vaccines

By Indication

  • Oncology
  • Ophthalmic Disorders
  • Immunology
  • Cardiovascular Disorders
  • Infectious Diseases
  • Genetic Disorders
  • CNS Disorders
  • Others

By Type

  • siRNA
  • ASO
  • mRNA
  • saRNA
  • miRNA
  • tRNA
  • Aptamers
  • Others

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The rna-based therapeutics and vaccines market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis 

Download Free Sample Report

Frequently Asked Questions

The rna-based therapeutics and vaccines market size was valued at US$ 61,296.3 million in 2023 and is set to grow at a significant CAGR of 3.8% from 2024-2030.

Arrowhead Pharmaceuticals, Inc., BioNTech AG, CureVac AG, Dicerna Pharmaceuticals, Inc., Marina Biotech, Inc., miRagen Therapeutics, Inc.

North-America is the fastest-growing region in the market

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2.  Global RNA Based Therapeutics and Vaccines Introduction 
2.1. Global RNA Based Therapeutics and Vaccines  - Taxonomy
2.2. Global RNA Based Therapeutics and Vaccines  - Definitions
2.2.1. Product
2.2.2. Indication
2.2.3. Type
2.2.4. Region
3. Global RNA Based Therapeutics and Vaccines Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Key Developments
3.6. Pipeline Analysis
3.7. M&A Activities
4. Global RNA Based Therapeutics and Vaccines  By Product, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
4.1. RNA based Therapeutics
4.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
4.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.1.3. Market Opportunity Analysis 
4.2. RNA based Vaccines
4.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.2.3. Market Opportunity Analysis 
5. Global RNA Based Therapeutics and Vaccines  By Indication, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
5.1. Oncology
5 1 1  Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Ophthalmic Disorders
5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Immunology
5.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Cardiovascular Disorders
5.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Infectious Diseases
5.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Genetic Disorders
5.6.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
5.7. CNS Disorders
5.7.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis 
5.8. Others
5.8.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis 
6. Global RNA Based Therapeutics and Vaccines  By Type, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
6.1. siRNA
6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. ASO
6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. mRNA
6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. saRNA
6.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. miRNA
6.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. tRNA
6.6.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
6.7. Aptamers
6.7.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis 
6.8. Others
6.8.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.8.3. Market Opportunity Analysis 
7.  Global RNA Based Therapeutics and Vaccines  By Region, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Europe
7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Asia Pacific
7.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Latin America
7.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. MEA
7.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
7.6.  Global RNA Based Therapeutics and Vaccines - Opportunity Analysis Index, By Indication, Product, Type,  ,  ,  ,  , and Region, 2024-2030
8. North America RNA Based Therapeutics and Vaccines, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
8.1. Product Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1. RNA based Therapeutics
8.1.2. RNA based Vaccines
8.2. Indication Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.2.1. Oncology
8.2.2. Ophthalmic Disorders
8.2.3. Immunology
8.2.4. Cardiovascular Disorders
8.2.5. Infectious Diseases
8.2.6. Genetic Disorders
8.2.7. CNS Disorders
8.2.8. Others
8.3. Type Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.3.1. siRNA
8.3.2. ASO
8.3.3. mRNA
8.3.4. saRNA
8.3.5. miRNA
8.3.6. tRNA
8.3.7. Aptamers
8.3.8. Others
8.4. Country Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.4.1. USA
8.4.2. Canada
9. Europe RNA Based Therapeutics and Vaccines, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
9.1. Product Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1. RNA based Therapeutics
9.1.2. RNA based Vaccines
9.2. Indication Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1. Oncology
9.2.2. Ophthalmic Disorders
9.2.3. Immunology
9.2.4. Cardiovascular Disorders
9.2.5. Infectious Diseases
9.2.6. Genetic Disorders
9.2.7. CNS Disorders
9.2.8. Others
9.3. Type Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1. siRNA
9.3.2. ASO
9.3.3. mRNA
9.3.4. saRNA
9.3.5. miRNA
9.3.6. tRNA
9.3.7. Aptamers
9.3.8. Others
9.4. Country Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1. Germany
9.4.2. France
9.4.3. Italy
9.4.4. UK
9.4.5. Russia
9.4.6. Rest of Europe
10. Asia Pacific RNA Based Therapeutics and Vaccines, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
10.1. Product Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1. RNA based Therapeutics
10.1.2. RNA based Vaccines
10.2. Indication Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1. Oncology
10.2.2. Ophthalmic Disorders
10.2.3. Immunology
10.2.4. Cardiovascular Disorders
10.2.5. Infectious Diseases
10.2.6. Genetic Disorders
10.2.7. CNS Disorders
10.2.8. Others
10.3. Type Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1. siRNA
10.3.2. ASO
10.3.3. mRNA
10.3.4. saRNA
10.3.5. miRNA
10.3.6. tRNA
10.3.7. Aptamers
10.3.8. Others
10.4. Country Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1. China
10.4.2. India
10.4.3. Japan
10.4.4. ANZ
10.4.5. South East Asia
10.4.6. Rest of APAC
11. Latin America RNA Based Therapeutics and Vaccines, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
11.1. Product Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1. RNA based Therapeutics
11.1.2. RNA based Vaccines
11.2. Indication Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1. Oncology
11.2.2. Ophthalmic Disorders
11.2.3. Immunology
11.2.4. Cardiovascular Disorders
11.2.5. Infectious Diseases
11.2.6. Genetic Disorders
11.2.7. CNS Disorders
11.2.8. Others
11.3. Type Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1. siRNA
11.3.2. ASO
11.3.3. mRNA
11.3.4. saRNA
11.3.5. miRNA
11.3.6. tRNA
11.3.7. Aptamers
11.3.8. Others
11.4. Country Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Argentina
11.4.4. Chile
11.4.5. Rest of LA
12. MEA RNA Based Therapeutics and Vaccines, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million)
12.1. Product Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1. RNA based Therapeutics
12.1.2. RNA based Vaccines
12.2. Indication Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1. Oncology
12.2.2. Ophthalmic Disorders
12.2.3. Immunology
12.2.4. Cardiovascular Disorders
12.2.5. Infectious Diseases
12.2.6. Genetic Disorders
12.2.7. CNS Disorders
12.2.8. Others
12.3. Type Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1. siRNA
12.3.2. ASO
12.3.3. mRNA
12.3.4. saRNA
12.3.5. miRNA
12.3.6. tRNA
12.3.7. miRNA
12.3.8. Others
12.4. Country Analysis,  2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1. Saudi Arabia
12.4.2. South Africa
12.4.3. UAE
12.4.4. Israel
12.4.5. Rest of MEA
13.  Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Moderna Therapeutics, Inc.
13.2.2. Alnylam Pharamceuticals, Inc.
13.2.3. Arbutus Biopharma Corp
13.2.4. Sylentis S.A.
13.2.5. Santaris Pharma A/S.
13.2.6. Arrowhead Pharmaceuticals, Inc.
13.2.7. BioNTech AG
13.2.8. Regulus Therapeutics, Inc.
13.2.9. CureVac, AG
13.2.10. Dicerna Pharmaceuticals, AG
13.2.11. Novo Nordisk
13.2.12. miRagen Therapeutics
13.2.13. Sarepta Therapeutics
13.2.14. Pfizer Inc
14.  Research Methodology
15.  Key Assumptions and Acronyms

Key Market Players

  • Moderna Therapeutics, Inc.
  • Alnylam Pharamceuticals, Inc.
  • Arbutus Biopharma Corp
  • Sylentis S.A.
  • Santaris Pharma A/S.
  • Arrowhead Pharmaceuticals, Inc.
  • BioNTech AG
  • Regulus Therapeutics, Inc.
  • CureVac, AG
  • Dicerna Pharmaceuticals, AG
  • Marina Biotech, Inc.
  • miRagen Therapeutics
  • Quark Pharmaceuticals, Inc.
  • Pfizer Inc

Related Industry Reports